Idiopathic Intracranial Hypertension Clinical Trials
Here are the 0 most popular medical studies for idiopathic intracranial hypertension
Frequently Asked Questions
Introduction to idiopathic intracranial hypertension
What are the top hospitals conducting idiopathic intracranial hypertension research?
In the realm of medical research, there are hospitals that dedicate their efforts to investigating even the rarest and most complex conditions. Idiopathic intracranial hypertension (IIH) is a condition that affects a small yet significant number of individuals worldwide. In Aurora, Colorado, the UCHealth Sue Anschutz-Rodgers Eye Center at Anschutz Medical Campus leads the charge with one active IIH trial and an all-time record of one completed trial. This cutting-edge institution made its mark by initiating its first IIH study in 2022. Similarly, Neuro-Eye Clinical Trials Inc., based in Houston, Texas, focuses on advancing our understanding of IIH through a single ongoing trial and has achieved one successful investigation since embarking on this field also in 2022.
Traveling south to Miami's University of Miami Leonard M. Miller School of Medicine - Bascom Palmer Eye Institute unveils another pivotal player determined to unravel the mysteries surrounding IIH. With one active clinical trial currently underway and an impressive track record of conducting one prior study on this condition since their very first recorded venture into it backin 2022serves as solid proof for their commitment towards improving treatments available for such patients.
The pursuit for knowledge extends further north to Minneapolis where University of Minnesota Health joins the mission against IIH with equal vigor—boasting one ongoing clinical trial focusing solely on tackling this challenging disorder while having accomplished another successful investigatory project starting from same point just two years ago in 2022 itself It’s clear these institutions are prioritizing advancements related specifically towards idiopathic intracranial hypertension
Lastly but certainly not least important we find New York Eye and Ear Infirmary of Mount Sinai situated amidst bustling city streets which houses equally enthusiastic researchers dedicated exclusively to exploring every facet within scopeof idiopathic intracranial hypertension; they have currently initiated third clinical test whilst successfully completingpast endeavors begunright alongside others across globe in 2022.
These hospitals, scattered across the country from Aurora to Houston, Miami to Minneapolis, and New York City, demonstrate a shared commitment to unraveling the complexities of idiopathic intracranial hypertension. Their efforts offer hope not just for those directly affected by this condition but for medical science as a whole. With each new study conducted and every data point analyzed, we inch closer towards unlocking innovative treatments that will undoubtedly enhance the lives of countless individuals facing this challenging disorder.
Which are the best cities for idiopathic intracranial hypertension clinical trials?
When it comes to idiopathic intracranial hypertension clinical trials, several cities are leading the way in research and development. New York, New York stands out with 2 active trials investigating treatments like Presendin and Venous sinus stenting (Serenity River). In addition, Aurora, Colorado; Houston, Texas; Miami, Florida; and Minneapolis, Minnesota. New York, New York stands out with 2 active trials investigating treatments like Presendin and Venous sinus stenting (Serenity River). In addition, Aurora, Colorado; Houston, Texas; Miami, Florida; and Minneapolis, Minnesota each have 1 active trial focusing on treatment options such as Presendin. These cities offer individuals with idiopathic intracranial hypertension access to cutting-edge clinical trials that aim to advance our understanding of the condition and improve patient outcomes.
Which are the top treatments for idiopathic intracranial hypertension being explored in clinical trials?
Clinical trials hold promise for advancing the treatment of idiopathic intracranial hypertension, with several interventions being explored. Among these treatments are Presendin, a promising drug currently undergoing one active trial dedicated to this condition. Equally noteworthy is venous sinus stenting (Serenity River), an innovative procedure also being tested in one ongoing trial. Another avenue of exploration is MRI structural brain imaging, which offers valuable insights and is the focus of another active study. Lastly, dural venous sinus stenting, introduced in 2020, holds potential as evidenced by its current participation in a clinical trial for idiopathic intracranial hypertension. These research efforts pave the way towards improved management options for individuals affected by this challenging condition.
What are the most recent clinical trials for idiopathic intracranial hypertension?
Exciting developments in the field of idiopathic intracranial hypertension are emerging through recent clinical trials. One such trial focuses on Presendin, a potential treatment for this condition. Currently in Phase 3, this investigational therapy aims to provide new options for patients suffering from idiopathic intracranial hypertension. With hopeful results expected from this study, individuals affected by this challenging disorder can look forward to improved management and quality of life in the near future.
What idiopathic intracranial hypertension clinical trials were recently completed?
Recently completed clinical trials for idiopathic intracranial hypertension (IIH) have made significant strides in advancing our understanding and treatment of this condition. Notably, a trial focused on Uproleselan sponsored by Washington University School of Medicine concluded in October 2021. Additionally, the National Cancer Institute wrapped up a study investigating mRNA-1273 in September 2021. These recent achievements underscore the commitment of researchers to combatting IIH and provide hope for patients grappling with this perplexing disorder.